Sandu Pharmaceuticals Profit & Loss Annual

BSE: 524703 | NSE: - | ISIN: INE751D01014 | Sector: Biotechnology & Drugs

35.66 +0.56 (1.60%)Updated : 16 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	67.61	65.10	65.57	63.38
Other Net	0.44	0.12	0.38	0.27
Diluted Weighted Average Shares	0.97	0.97	0.97	0.94
Depreciation/ Amortization	0.68	0.67	0.58	0.52
Operating Income	2.32	2.09	1.71	1.97
Net Income	1.77	1.55	1.46	1.52
Income Availableto Com Excl Extra Ord	1.77	1.55	1.46	1.52
Other Operating Expenses Total	24.67	21.41	22.34	20.58
Net Income Before Taxes	2.66	2.16	2.07	2.22
Net Income After Taxes	1.77	1.55	1.46	1.52
Income Availableto Com Incl Extra Ord	1.77	1.55	1.46	1.52
Costof Revenue Total	31.57	32.10	32.57	31.19
Gross Profit	38.36	35.09	34.71	34.16
Interest Inc( Exp) Net- Non- Op Total	-0.11	-0.05	-0.02	-0.02
Unusual Expense( Income)	0.00	0.00	0.00	0.00
Diluted Net Income	1.77	1.55	1.46	1.52
DPS- Common Stock Primary Issue	1.00	0.80	0.80	0.75
Provisionfor Income Taxes	0.89	0.61	0.61	0.70
period Type	-	-	-	-
Net Income Before Extra Items	1.77	1.55	1.46	1.52
Total Revenue	69.93	67.19	67.28	65.35
period Length	12.00	12.00	12.00	12.00
Revenue	69.93	67.19	67.28	65.35
Selling/ General/ Admin Expenses Total	10.69	10.92	10.07	11.10
Diluted Normalized EPS	1.83	1.60	1.51	1.61
Diluted EPS Excluding Extra Ord Items	1.83	1.60	1.51	1.61
Total Adjustmentsto Net Income	-	-	0.00	-